Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Jacques

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Life (Basel, Switzerland)|March 28, 2024
In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-ImmunotherapyCamille Jacques, Flora Marchand, Mathias Chatelais, et al.
International Journal of Molecular Sciences|May 14, 2025
Active Substances from the Micro-Immunotherapy Medicine 2LC1<sup>®</sup> Show In Vitro Anti-Cancer Properties in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities in Human MacrophagesCamille Jacques, Irene Marchesi, Francesco Paolo Fiorentino, et al.
International Journal of Molecular Sciences|January 11, 2022
The Micro-Immunotherapy Medicine 2LEID Exhibits an Immunostimulant Effect by Boosting Both Innate and Adaptive Immune ResponsesCamille Jacques, Mathias Chatelais, Karim Fekir, et al.
Current Issues in Molecular Biology|June 26, 2026
In Vitro Effects of the Three Actives IL-12 (5 CH), IFN-γ (6 CH), and TNF-α (5 CH) from the Micro-Immunotherapy Medicine 2LEID-N<sup>®</sup> on Several Populations of Immune CellsCamille Jacques, Flora Marchand, Mathias Chatelais, et al.
Cells|April 2, 2020
Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone SarcomasCamille Jacques, Robel Tesfaye, Melanie Lavaud, et al.
Epigenomics|December 19, 2019
BET bromodomains' functions in bone-related pathologiesCamille Jacques, Melanie Lavaud, Steven Georges, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 8, 2019
Murine Models of Bone SarcomasCamille Jacques, Nathalie Renema, Benjamin Ory, et al.
Oncotarget|August 4, 2016
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumorsCamille Jacques, Lidia Rodriguez Calleja, Marc Baud'huin, et al.
Journal of Bone Oncology|June 1, 2018
Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitationsCamille Jacques, Nathalie Renema, Frederic Lezot, et al.
International Journal of Molecular Sciences|June 10, 2022
A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma ModelCamille Jacques, Irene Marchesi, Francesco Paolo Fiorentino, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Life (Basel, Switzerland)|March 28, 2024
In Vitro Study of Interleukin-6 when Used at Low Dose and Ultra-Low Dose in Micro-ImmunotherapyCamille Jacques, Flora Marchand, Mathias Chatelais, et al.
International Journal of Molecular Sciences|May 14, 2025
Active Substances from the Micro-Immunotherapy Medicine 2LC1<sup>®</sup> Show In Vitro Anti-Cancer Properties in Colon, Prostate, and Breast Cancer Models and Immune-Enhancing Capabilities in Human MacrophagesCamille Jacques, Irene Marchesi, Francesco Paolo Fiorentino, et al.
International Journal of Molecular Sciences|January 11, 2022
The Micro-Immunotherapy Medicine 2LEID Exhibits an Immunostimulant Effect by Boosting Both Innate and Adaptive Immune ResponsesCamille Jacques, Mathias Chatelais, Karim Fekir, et al.
Current Issues in Molecular Biology|June 26, 2026
In Vitro Effects of the Three Actives IL-12 (5 CH), IFN-γ (6 CH), and TNF-α (5 CH) from the Micro-Immunotherapy Medicine 2LEID-N<sup>®</sup> on Several Populations of Immune CellsCamille Jacques, Flora Marchand, Mathias Chatelais, et al.
Cells|April 2, 2020
Implication of the p53-Related miR-34c, -125b, and -203 in the Osteoblastic Differentiation and the Malignant Transformation of Bone SarcomasCamille Jacques, Robel Tesfaye, Melanie Lavaud, et al.
Epigenomics|December 19, 2019
BET bromodomains' functions in bone-related pathologiesCamille Jacques, Melanie Lavaud, Steven Georges, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 8, 2019
Murine Models of Bone SarcomasCamille Jacques, Nathalie Renema, Benjamin Ory, et al.
Oncotarget|August 4, 2016
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumorsCamille Jacques, Lidia Rodriguez Calleja, Marc Baud'huin, et al.
Journal of Bone Oncology|June 1, 2018
Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitationsCamille Jacques, Nathalie Renema, Frederic Lezot, et al.
International Journal of Molecular Sciences|June 10, 2022
A Micro-Immunotherapy Sequential Medicine MIM-seq Displays Immunomodulatory Effects on Human Macrophages and Anti-Tumor Properties towards In Vitro 2D and 3D Models of Colon Carcinoma and in an In Vivo Subcutaneous Xenograft Colon Carcinoma ModelCamille Jacques, Irene Marchesi, Francesco Paolo Fiorentino, et al.
Pageof 3